Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5443_Библиотеки_им_академика_М_И_Перельмана
.pdf
12.7.2 Emerging technologies
New technologies that have the potential to revolutionize simulation systems have
emerged in recent years. For example, quantum computing provides extraordinary
computational capability for simulating complicated chemical interactions. Its pro-
spective use in DD simulations offers the promise of increased accuracy and speed.
Furthermore, to improve predictive modeling, machine learning and artificially intel-
ligent (AI) systems are being incorporated into simulations. These technologies may
adjust to and acquire information from real-world data, making simulation systems
more flexible and responsive.
12.7.3 Quantum computing
Quantum computing is an innovative system that employs quantum mechanics to do
exceedingly rapid and sophisticated calculations. It has the ability to considerably im-
prove simulation understanding of the way nanocarriers operate at the molecular
level in the context of medication delivery [98]. This can lead to extremely accurate
predictions about how different carriers affect drug delivery. Quantum computing en-
ables simulations to take into account a broader range of parameters and interac-
tions, resulting in more precise nanocarrier selection.
12.7.4 Machine learning and artificial intelligence
Simulation systems are being transformed by machine learning and AI. These technolo-
gies can analyze and learn from large datasets, allowing simulations to modify and im-
prove over time. AI can optimize nanocarrier selection in the field of medicine delivery
by continuously improving models, according to experimental data and outcomes in
clinical trials. AI-powered simulations can forecast which of the nanocarriers will be
most successful in specific patient groups, thereby speeding up the development of per-
sonalized medication delivery systems [99].
12.7.5 In silico clinical trials
The approach behind in silico clinical trials is revolutionizing drug development.
These studies involve replicating the effect of drug candidate including nanocarriers
within a virtual (simulated) clinical environment. They can simulate a wide range of
the physiological circumstances and patient responses. In silico clinical trials tend to
be a game changer for nanocarrier selection because they enable researchers to de-
termine the safety as well as effectiveness of carriers in clinical trials without the
12 Application of simulation system for selection of nanocarrier 293
https://t.me/med1917
need for significant human testing. This method offers the potential to drastically cut
the time and expense of drug development [100].
12.7.6 Parameterization and improved force fields
Advances in force field technologies and parameterization techniques are improving
simulation accuracy. These advancements enable more precise modeling of molecular
interactions, increasing the reliability of simulations in predicting the behavior of
nanocarriers. Researchers can better determine ideal nanocarriers for medication de-
livery by enhancing the depiction of molecular forces or interactions [101].
12.7.7 Multiscale simulations
Multiscale simulations include many levels of modeling, ranging from quantum phys-
ics to continuum mechanics. This method allows for the investigation of nanocarriers
at various sizes, from tiny molecules to macroscopic carriers’ behavior. Multiscale
simulations offer a full perspective of drug–carrier interactions that are especially
useful for comprehending complex systems. They can help lead the development of
nanocarriers that work well in a variety of biological settings.
These new technologies and approaches have a lot of potential for the development
of DD and nanocarrier screening. They hold the promise of more precise, efficient, and
personalized DDSs. As these developments continue to evolve, the pharmaceutical de-
velopment field will see a substantial ch ange towards smarter, more information-
based, and patient-centric approaches.
12.7.8 High-performance computing and parallel processing
Simulations run faster and more effectively thanks to developments in parallel process-
ing and high-performance computing. Today, days or weeks can be saved by completing
complex simulations in a fraction of the time. The iterative process of designing and
selecting nanocarriers depends on this acceleration. More thorough parameter studies
and simulations using larger datasets allow scientists to gain a deeper knowledge of the
performance of nanocarriers in a variety of scenarios. Faster research project turn-
around times result from this enhanced computational speed, which eventually speeds
up the creation of innovative medication delivery systems [102].
294 Abhishek Singh et al.
https://t.me/med1917
12.7.9 Virtual reality (VR) and interactive simulations
A new level of engagement is added to simulation systems by the integration of vir-
tual reality (VR). Through VR, scientists can fully submerge themselves in a simulated
setting, facilitating a more intuitive investigation of molecular interactions and struc-
tures. This degree of immersion fosters innovation in nanocarrier design by improv-
ing comprehension of complex systems. VR simulations can offer a three-dimensional
representation of molecular interactions in terms of nanocarrier selection, which can
help with better understanding of how carriers move through the biological environ-
ment [103]. Through virtual testing, researchers may watch the dynamic behavior of
nanocarriers in real-time. This improves decision-making and stimulat es new ideas
for tailored medicine delivery through the design of nanocarriers.
12.7.10 Interdisciplinary collaboration: catalyzing progress
in drug discovery
The collaborative partnership between pharmaceutical researchers and computer sci-
entists is a critical element for advancement and innovation in the intricate field of
drug discovery. This section highlights the critical significance of this interdisciplinary
collaboration and provides insight into how teamwork might advance the area [104].
12.7.11 Taking down silos: the importance of collaboration
Harnessing computational power:
– Computational scientists contribute sophisticated modeling strategies, data ana-
lytics, and simulation approaches.
– Their knowledge makes it possible to simulate intricate biological processes, fore-
cast molecular interactions, and analyze enormous datasets.
Insights from pharmaceutical scientists:
– Pharmaceutical resea rchers contribute domain-specific knowledge, understand-
ing the intricacies of disease pathways, drug targets, and experimental outcomes.
– Their practical insights guide the selection of promising compounds, experimen-
tal design, and validation of computational predictions.
Accelerating drug discovery:
– By merging computational prowess with pharmaceutical insights, the collabora-
tive effort accelerates the drug discovery pipeline.
– Computational models can rapidly screen vast chemical libraries, narrowing
down potential drug candidates for further experimental validation [105].
12 Application of simulation system for selection of nanocarrier 295
https://t.me/med1917
Advancing the field through interdisciplinary efforts
Precision medicine:
– Computational models, informed by pharmaceutical insights, facilitate the design
of personalized treatment strategies.
– Tailoring drug interventions to individual genetic and molecular profiles becomes
feasible, paving the way for precision medicine.
Optimizing drug formulations:
– Collaboration aids in the optimization of drug formulations for enhanced bio-
availability, stability, and targeted delivery.
– Computational models predict how changes in formulation impact drug release
kinetics, guiding experimental efforts for optimal formulations.
Navigating biological complexity:
– The collaboration helps tackle the inherent complexity of biological systems.
– Computational models can simulate intricate molecular interactions, while phar-
maceutical researchers provide real-world context, allowing for a more compre-
hensive understanding.
Innovative therapeutic approaches:
– Interdisciplinary efforts foster creativity and innovation, leading to the explora-
tion of novel therapeutic approaches.
– The combination of computational predictions and pharmaceutical expertise can
uncover unconventional drug targets and design strategies [106].
Challenges and potential solutions
Communication and language:
– Bridging the gap between computational and pharmaceutical language is crucial.
– Establishing clear communication channels, shared terminology, and collabora-
tive platforms facilitate effective interdisciplinary interactions.
Data integration:
– Integrating diverse datasets, ranging from computational simulations to experi-
mental results, poses challenges.
– Developing standardized approaches for data integration and sharing ensures a
holistic view of drug discovery efforts.
The secret to revolutionary breakthroughs in drug discovery lies in the collaboration be-
tween pharmaceutical researchers and computational scientists. This cross-disciplinary
cooperation creates opportunities for ground-breaking inventions while also quickening
the rate of discovery. In order to continue pushing the envelope of what is possible in
the search for innovative and successful therapies, it will be crucial that we cultivate a
culture of cooperation, deal with obstacles, and develop a variety of skill sets.
296 Abhishek Singh et al.
https://t.me/med1917
12.8 Guidelines for effective simulation studies:
navigating ethical considerations and ensuring
data validity
Simulator studies are complex projects that need to be carefully planned, carried out,
and ethically considered. The principles below provide as a compass for students en-
tering this dynamic professi on, stressing ethical behavior and validating the gener-
ated data, all the while navigating the intricacies of simulation studies [107].
12.8.1 Clearly define objectives and scope
Begin by articulating the specific objectives of your simulation study. Clearly define
the research questions you aim to answer and outline the scope of your simulation.
This clarity is fundamental to maintaining focus throughout the study.
12.8.2 Thorough literature review
To comprehend the current state of the selected simulation domain, conduct a thor-
ough literature review. This helps you focus your research questions and guarantees
that the body of information already in existence is meaningfully added to by your
effort.
12.8.3 Select appropriate simulation tools and models
Choose simulation tools and models that align with your research objectives. Evaluate
the strengths and limitations of different tools and models, ensuring that they are
well-suited to address the specific aspects of your study [108].
12.8.4 Ethical considerations
12.8.4.1 Privacy and confidentiality
Prioritize the protection of sensitive information. Ensure that any data used in the
simulation, especially if derived from real-world sources, is anonymized and adheres
to privacy standards.
Clearly outline how confidentiality will be maintained throughout the study.
12 Application of simulation system for selection of nanocarrier 297
https://t.me/med1917
12.8.4.2 Informed consent
If your simulation involves human subjects, secure informed consent. Clearly commu-
nicate the purpose, risks, and benefits of the study to participants, ensuring that their
participation is voluntary.
12.8.4.3 Responsible use of data
Adhere to ethical standards in data collection and use. Avoid any manipulation of
data that could lead to biased results or misrepresentation [109].
Transparently report any limitations or potential biases in the data.
12.8.5 Rigorous data validation
12.8.5.1 Input data quality
Validate the quality of input data. Any inaccuracies or biases in the initial data can
propagate through the simulation, impacting the validity of results.
Implement procedures to identify and correct errors in the input data.
12.8.5.2 Model validation
Rigorously validate the chosen simulation model. This involves comparing simulation
results with real-world observations or empirical data.
Clearly document the validation process and address any discrepancies found.
12.8.6 Sensitivity analysis
Conduct sensitivity analysis to understand the robustness of your simulation model.
Identify key parameters and evaluate how variations in these parameters impact the
outcomes. This helps in gauging the reliability of your results.
12.8.7 Reproducibility
Ensure that your simulation study is reproducible. Document the entire simulation
process, including code, parameters, and data sources, in a manner that allows others
to replicate your work. Reproducibility enhances the credibility of your findings.
298 Abhishek Singh et al.
https://t.me/med1917
12.8.8 Iterative refinement
Recognize that simulation studies are often iterative processes. As you progress, be
open to refining your model, incorporating new data, and adjusting parameters based
on emerging insights. This iterative approach enhances the accuracy and applicability
of your simulation.
12.8.9 Collaboration and peer review
12.8.9.1 Collaboration
Encourage collaboration with peers and experts in the field. Engaging with others can
bring diverse perspectives, improving the overall quality of your simulation study [110].
Seek feedback at various stages of your study, from conceptualization to final
results.
12.8.9.2 Peer review
Prioritize peer review as an integral part of your simulation study. Submit your work
to reputable journals or present it at conferences to undergo thorough evaluation by
peers in the field.
12.8.9.3 Transparent reporting
In your final documentation, ensure transparent reporting of your methods, assump-
tions, and results. Clearly articulate the limitations of your study and acknowledge
uncertainties. Transparent reporting contributes to the overall integrity of your
research.
12.8.9.4 Nurturing ethical simulation practices
Although simulation studies have great potential to advance knowledge and solve dif-
ficult problems, data veracity and ethical behavior are crucial. Students can ensure
the rigor of their research and the ethical integrity necessary for the responsible ad-
vancement of knowledge by adhering to these criteria before beginning their simula-
tion studies. The foundation of significant and reliable simulation research will
continue to be an unwavering dedication to ethical behaviors and data validity, even
as technology and methodology advance [111].
12 Application of simulation system for selection of nanocarrier 299
https://t.me/med1917
12.9 Conclusion
A crucial step toward transforming drug delivery in the field of nanomedicine is the
investigation of simulation systems for nanocarrier selection in biopharmaceutically de-
manding drugs. The complicated relationship that exists between biological entities and
pharmacological formulations necessitates a sophisticated knowledge, and simulation
systems prove to be invaluable resources in this regard. Because biopharmaceutically
demanding medications are complex, drug delivery must be customized, and nanocar-
riers are leading the way in this area of innovation. Researchers can fine-tune carrier
qualities to achieve optimal treatment effects by gaining unique insights into the dy-
namic interactions taking place at the nanoscale through the lens of simulation systems.
The use of simulation tools to model and forecast the behavior of nanocarriers in bio-
logical settings speeds up the process of developing new drugs and reduces the risk in-
volved in making mistakes during experimentation. This quickens the rate of invention
and boosts the productivity of pharmaceutical research, which eventually results in
safer and more effective therapies for difficult-to-treat illnesses. Additionally, the use of
simulation systems in the medication development proc ess promotes a paradigm
change in favor of precision medicine. A customized and tailored approach to therapy
is made possible by tailoring nanocarriers to the unique properties of biopharmaceuti-
cally difficult drugs, thereby minimizing adverse effects and optimizing therapeutic effi-
cacy. This is a big step toward patient-centric healthcare, where the best medicines are
customized to each patient’s unique profile, in addition to being efficacious. Nonethe-
less, it is imperative to recognize the persistent obstacles and constraints within the do-
main of simulation syst ems for nanocarrier selection. To ensure the accuracy and
dependability of simulation results, it is essential that simulation models be continu-
ously improved, validated against experimental data, and collaboratively worked on by
diverse teams. To put it simply, the exploration of simulation systems for nanocarrier
selection in biopharmaceutically demanding drugs is a continual journey, characterized
by notable advancements and constant change. The combination of simulation technol-
ogy with pharmaceutical innovation has the potential to revolutionize the way we
think about and tackle medication delivery problems as science and technology prog-
ress. This chapter emphasizes how simulation will play a critical role in defining the
field of nanomedicine in the future, as the combination of biological complexity and
computer power will create new avenues for the development of safer, more efficient,
and customized therapeutic interventions.
References
[1] Nagpal, S., Braner, S., Modh, H., Tan, A. X. X., Mast, M.-P., Chichakly, K., et al. A physiologically-
based nanocarrier biopharmaceutics model to reverse-engineer the in vivo drug release. European
Journal of Pharmaceutics and Biopharmaceutics, 2020, 153, 257–272.
300 Abhishek Singh et al.
https://t.me/med1917
[2] Choudhury, H., Maheshwari, R., Pandey, M., Tekade, M., Gorain, B., & Tekade, R. K. Advanced
nanoscale carrier-based approaches to overcome biopharmaceutical issues associated with
anticancer drug ‘Etoposide. Materials Science and Engineering: C, 2020, 106, 110275.
[3] Kuentz, M. Lipid-based formulations for oral delivery of lipophilic drugs. Drug Discovery Today:
Technologies, 2012, 9(2), e97–104.
[4] Pant, A., Sharma, G., Saini, S., Kaur, G., Jain, A., Thakur, A., et al. QbD-driven development of
phospholipid-embedded lipidic nanocarriers of raloxifene: Extensive in vitro and in vivo evaluation
studies. Drug Delivery and Translational Research, 2023, 1–27; 2024 Mar;14(3):730–56.
[5] Nerli, G., Gonçalves, L. M. D., Cirri, M., Almeida, A. J., Maestrelli, F., Mennini, N., et al. Design,
evaluation and comparison of nanostructured lipid carriers and Chitosan nanoparticles as carriers
of poorly soluble drugs to develop oral liquid formulations suitable for pediatric use.
Pharmaceutics, 2023, 15(4), 1305.
[6] Sharma, N., Vasisht, K., Kaur, J., Sandhu, S. K., Dey, K., Hameed, B. A., et al. Blending ethnomedicine
with modern technology – from conventional to Tailored products: Modulating biopharmaceutical
properties of berberis extract by solid lipid nanoparticles for wound healing. Journal of Functional
Biomaterials, 2023, 14(8), 418.
[7] Xu, K., Li, S., Zhou, Y., Gao, X., Mei, J., & Liu, Y. Application of computing as a high-practicability
and-efficiency auxiliary tool in nanodrugs discovery. Pharmaceutics, 2023, 15(4), 1064.
[8] Suyal, J., Kumar, B., & Jakhmola, V. Novel approach self-nanoemulsifying drug delivery system: A
review. Advances in Pharmacological and Pharmaceutics, 2023, 11(2), 131–139.
[9] Lukova, P., & Katsarov, P. Contemporary aspects of designing marine polysaccharide microparticles
as drug carriers for biomedical application. Pharmaceutics, 2023, 15(8), 2126.
[10] Kesharwani, P., Deepika, D., Bharti, K., Jain, A., Sharma, S., Mishra, B., et al. Pharmacotherapeutic
and computational approaches for biopharmaceutical considerations towards drug development
and delivery against COVID-19. Letters in Applied NanoBioScience, 2023, 12(4), 1–23.
[11] Saif, A., Anjum, L., Faisal, Z., Akram, N., Shah, Y. A., Irfan, R., et al. Recent advances in protein-based
nanoparticles and their applications in the delivery of bioactive compounds. International Journal of
Food Properties, 2023, 26(2), 2881–2895.
[12] Jandhyala, R., & Rout, R. Observing expert opinion of medical affairs pharmaceutical physicians on
the value of their clinical experience to the pharmaceutical industry using the Jandhyala method.
Current Medical Research and Opinion, 2023, 1–10; 2023 Dec 2;39(12):1541–50.
[13] Kumar, G. Securing pharmaceutical supply chain using digital drug serialization. World Journal of
Advanced Engineering Technologies and Sciences, 2023, 10(01), 15–20.
[14] Haider, R. Pharmaceutical and biopharmaceuticals industries: Revolutionizing healthcare. Asian
Journal of Nature and Science, 2023, 2(2), 69–80.
[15] Augustijns, P., & Brewster, M. E. Supersaturating drug delivery systems: Fast is not necessarily good
enough. Journal Pharmaceutical Sciences, 2012, 101(1), 7–9.
[16] Kumar, A., Ahuja, A., Ali, J., & Baboota, S. Conundrum and therapeutic potential of curcumin in drug
delivery. Critical Reviews in Therapeutic Drug Carrier Systems, 2010, 27(4), 279–312.
[17] Wilczewska, A. Z., Niemirowicz, K., Markiewicz, K. H., & Car, H. Nanoparticles as drug delivery
systems. Pharmacol Reports, 2012, 64(5), 1020–1037.
[18] Khan, A. D., & Singh, L. Various techniques of bioavailability enhancement: A review. Journal of Drug
Delivery and Therapeutics, 2016, 6(3), 34–41.
[19] Zorzi, A., Linciano, S., & Angelini, A. Non-covalent albumin-binding ligands for extending the
circulating half-life of small biotherapeutics. Medchemcomm, 2019, 10(7), 1068–1081.
[20] Lee, J. H., & Yeo, Y. Controlled drug release from pharmaceutical nanocarriers. Chemical
Engineering Science, 2015, 125, 75–84.
12 Application of simulation system for selection of nanocarrier 301
https://t.me/med1917
[21] Crank, J., & Henry, M. E. Diffusion in media with variable properties. Part I. The effect of a variable
diffusion coefficient on the rates of absorption and desorption. Transactions of the Faraday Society,
1949, 45, 636–650.
[22] Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. Overcoming barriers to patient
adherence: The case for developing innovative drug delivery systems. Nature Reviews Drug
Discovery, 2023, 22(5), 387–409.
[23] Mohammad, W. A. M., Nazih Diab, Y., Elomri, A., & Triki, C. Innovative solutions in last mile delivery:
Concepts, practices, challenges, and future directions. In: Supply Chain Forum: An International
Journal. 2023, (pp. 151–169). Taylor & Francis.
[24] Dong, P., Rakesh, K. P., Manukumar, H. M., Mohammed, Y. H. E., Karthik, C. S., Sumathi, S., et al.
Innovative nano-carriers in anticancer drug delivery-a comprehensive review. Bioorganic Chemistry,
2019, 85, 325–336.
[25] Cowen, T., Karim, K., & Piletsky, S. Computational approaches in the design of synthetic receptors–A
review. Anal Chim Acta, 2016, 936, 62–74.
[26] Jung, Y. H., Kim, J. U., Lee, J. S., Shin, J. H., Jung, W., Ok, J., et al. Injectable biomedical devices for
sensing and stimulating internal body organs. Advances in Materials, 2020, 32(16), 1907478.
[27] Meng, W., He, C., Hao, Y., Wang, L., Li, L., & Zhu, G. Prospects and challenges of extracellular vesicle-
based drug delivery system: Considering cell source. Drug Delivery, 2020, 27(1), 585–598.
[28] Kaji, E. H., & Leiden, J. M. Gene and stem cell therapies. Jama, 2001, 285(5), 545–550.
[29] Alvarez-Lorenzo, C., & Concheiro, A. Smart drug delivery systems: From fundamentals to the clinic.
Chemical Communication, 2014, 50(58), 7743–7765.
[30] Ulldemolins, A., Seras-Franzoso, J., Andrade, F., Rafael, D., Abasolo, I., Gener, P., et al. Perspectives
of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics. Cancer
Drug Resistance, 2021, 4(1), 44.
[31] Klitou, P., Parisi, E., Bordignon, S., Bravetti, F., Rosbottom, I., Dell’Aera, M., et al. Navigating the
complex solid form landscape of the quercetin flavonoid molecule. Crystal Growth and Design,
2023, 23(8), 6034–6045.
[32] Hansson, T., Oostenbrink, C., & van Gunsteren, W. Molecular dynamics simulations. Current Opinion
in Structural Biology, 2002, 12(2), 190–196.
[33] Li, J., Zhang, J., Yang, X., Zhang, A., & Yu, M. Monte Carlo simulations of deformation behaviour of
unbound granular materials based on a real aggregate library. International Journal of Pavement
Engineering, 2023, 24(1), 2165650.
[34] Muhammad, U., Uzairu, A., & Ebuka Arthur, D. Review on: Quantitative structure activity relationship
(QSAR) modeling. Journal of Analytical and Pharmaceutical Research, 2018, 7(2), 240– 242.
[35] Somasundaram, T. S., & Govindarajan, K. CLOUDRB: A framework for scheduling and managing
High-Performance Computing (HPC) applications in science cloud. Future Generation Computer
Systems, 2014, 34, 47–65.
[36] Rai, V. K., Mishra, N., Yadav, K. S., & Yadav, N. P. Nanoemulsion as pharmaceutical carrier for dermal
and transdermal drug delivery: Formulation development, stability issues, basic considerations and
applications. Journal of Controlled Release, 2018, 270, 203–225.
[37] Peltier, S., Oger, J.-M., Lagarce, F., Couet, W., & Benoît, J.-P. Enhanced oral paclitaxel bioavailability after
administration of paclitaxel-loaded lipid nanocapsules. Pharmaceutical Research, 2006, 23, 1243–1250.
[38] Lyon, P. C., Gray, M. D., Mannaris, C., Folkes, L. K., Stratford, M., Campo, L., et al. Safety and
feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive
liposomes in liver tumours (TARDOX): A single-centre, open-label, phase 1 trial. Lancet Oncology,
2018, 19(8), 1027–1039.
[39] Korivi, M., Huang, Y.-W., & Liu, B. R. Cell-penetrating peptides as a potential drug delivery system
for effective treatment of diabetes. Current Pharmaceutical Design, 2021, 27(6), 816–825.
302 Abhishek Singh et al.
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана